Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. Read more about Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort. Read more about Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. Read more about IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Read more about A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia. Read more about Correction: Comprehensive Immunoprofiling of High-risk Oral Proliferative and Localized Leukoplakia.
Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma. Read more about Phase I Study of High-Dose L-methylfolate in Combination with Temozolomide and Bevacizumab in Recurrent IDH wild-type High-Grade Glioma.
Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia. Read more about Comprehensive Immunoprofiling of High-Risk Oral Proliferative and Localized Leukoplakia.
